Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
pharmaphorum4d
Roche, Boehringer tap biosensor firms for patient studies
Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring ...
pharmaphorum2d
Boehringer preps phase 3 for dual-action obesity drug
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...
GitHub4d
png-icons
Monico is a custom icon pack designed specifically for the Monobloc solution by crc.studio. It features a collection of versatile icons to enhance your design system, creating a cohesive visual ...
Post-Courier1d
Category: National News
David Kende Reali, a 30-year-old man from Idawi village in the Tari-Pori district of Hela province, is wanted by Gulf police.